Mimi D. Michaelson, Ph.D.
Affiliations: | 2002 | Harvard University, Cambridge, MA, United States |
Google:
"Mimi Michaelson"Mean distance: 15.4 (cluster 23) | S | N | B | C | P |
Parents
Sign in to add mentor| Howard Gardner | grad student | 2002 | Harvard | |
| (Poised to act: Profiles of fifteen young activists.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hussain M, Corn PG, Michaelson MD, et al. (2014) Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4218-27 |
| Sonpavde G, Pond GR, Armstrong AJ, et al. (2014) Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical Genitourinary Cancer. 12: 317-24 |
| Aizer AA, Paly JJ, Michaelson MD, et al. (2014) Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. Journal of Oncology Practice / American Society of Clinical Oncology. 10: 107-12 |
| Michaelson MD, Oudard S, Ou YC, et al. (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 76-82 |
| Sonpavde G, Pond GR, Armstrong AJ, et al. (2014) Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. Bju International. 114: E25-31 |
| Aizer AA, Paly JJ, Zietman AL, et al. (2013) Models of care and NCCN guideline adherence in very-low-risk prostate cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1364-72 |
| Lee RJ, Saylor PJ, Michaelson MD, et al. (2013) A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3088-94 |
| Saylor PJ, Mahmood U, Kunawudhi A, et al. (2012) Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 1670-5 |
| Aizer AA, Paly JJ, Zietman AL, et al. (2012) Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3071-6 |
| Saylor PJ, Michaelson MD. (2012) Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer? The Oncologist. 17: 288-90 |